In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for Compounded "semaglutide" is not FDA approved semaglutide.com Peptides Lack Reliable Safety Information, Watchdog Warns BPC 157 Banned: Key Facts on the Latest FDA Decision BPC 157 and the Difference Between an Evidence Gap and a Cover Up: What the entire human evidence base actually looks like, and the questions to ask next. WellFounded Founders Health & BPC 157: The peptide with big claims and scant evidence STAT